Edward B. Garon

ScholarGPS® ID: 51514594904147

Affiliation
University of California, Los Angeles, Westwood, Los Angeles, United States
Affiliation History

Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Lung Cancer | Non-small-cell Lung Carcinoma | Thorax | Neoplasm | Epidermal Growth Factor Receptor | Mutation | Immunotherapy | Erlotinib | Docetaxel | Chemotherapy | Nivolumab | Cancer Immunotherapy | Carboplatin | Radiation Therapy
Metrics Summary
Publication Count
400
Predicted Citations
47,892
Predicted h-index
72
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02. (journal article)
Patel, Jyoti D. | Cho, Byoung Chul | Cobo, Manuel | Reyes Cabanillas, Roxana | Vicente, David | Fuentes Pradera, Jose | Garon, Edward B. | Mok, Tony S. K. | Cappuzzo, Federico | Neal, Joel W. | ... | Reck, Martin
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 8592-8592 (2024).
10.1200/JCO.2024.42.16_suppl.8592
Cite | Source
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors. (journal article)
Falchook, Gerald Steven | LoRusso, Patricia | Goldman, Jonathan W. | El-Khoueiry, Anthony B. | Tolcher, Anthony W. | Xing, Yan | Henry, Jason Timothy | Keam, Bhumsuk | Kim, Dong-Wan | Kim, Tae-Yong | ... | Garon, Edward B.
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 2529-2529 (2024).
10.1200/JCO.2024.42.16_suppl.2529
Cite | Source
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations. (journal article)
Skoulidis, Ferdinandos | Borghaei, Hossein | Garon, Edward B. | Leal, Ticiana | Liu, Stephen V. | Nadler, Eric S. | Patel, Sandip Pravin | Velcheti, Vamsidhar | Gautam, Ashish | Emeribe, Ugochinyere | ... | Heymach, John
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS8655-TPS8655 (2024).
10.1200/JCO.2024.42.16_suppl.TPS8655
Cite | Source
60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study (journal article)
Cappuzzo, F. | Patel, J. | Cho, B.C. | Dols, M. Cobo | Cabanillas, R.M. Reyes | Baz, D. Vicente | Pradera, J. Fuentes | Neal, J. | Garon, E.B. | Mekan, S. | ... | Reck, M.
ESMO Open, volume 9 (2024).
10.1016/j.esmoop.2024.102639
Cite | Source
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer (journal article)
Wu, Trudy C. | Luterstein, Elaine | Neilsen, Beth K. | Goldman, Jonathan W. | Garon, Edward B. | Lee, Jay M. | Felix, Carol | Cao, Minsong | Tenn, Stephen E. | Low, Daniel A. | ... | Lee, Percy
JAMA Oncology, volume 10, issue 3, pages 352- (2024).
10.1001/jamaoncol.2023.6033
Cited by (3) | Cite | Source
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants (journal article)
Nishino, Kazumi | Shih, Jin-Yuan | Nakagawa, Kazuhiko | Reck, Martin | Garon, Edward B. | Carlsen, Michelle | Matsui, Tomoko | Visseren-Grul, Carla | Nadal, Ernest
JTO Clinical and Research Reports, volume 5, issue 2, pages 100624- (2024).
10.1016/j.jtocrr.2023.100624
Cite | Source
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial (journal article)
Garon, Edward B. | Lu, Shun | Goto, Yasushi | De Marchi, Pedro | Paz-Ares, Luis | Spigel, David R. | Thomas, Michael | Yang, James Chih-Hsin | Ardizzoni, Andrea | Barlesi, Fabrice | ... | Cho, Byoung Chul
Journal of Clinical Oncology, volume 42, issue 2, pages 180-191 (2024).
10.1200/JCO.23.00910
Cited by (6) | Cite | Source
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden (journal article)
Williamson, Timothy J. | Garon, Edward B. | Irwin, Michael R. | Choi, Alyssa K. | Goldman, Jonathan W. | Stanton, Annette L.
Psychosomatic Medicine, volume 86, issue 4, pages 334-341 (2024).
10.1097/PSY.0000000000001299
Cite | Source
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review (journal article)
Majem, Margarita | Basch, Ethan | Cella, David | Garon, Edward B. | Herbst, Roy S. | Leighl, Natasha B.
Lung Cancer, volume 187 (2024).
10.1016/j.lungcan.2023.107419
Cite | Source
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) (journal article)
Garon, Edward B. | Cho, Byoung Chul | Luft, Alexander | Alatorre-Alexander, Jorge | Geater, Sarayut Lucien | Kim, Sang-We | Ursol, Grygorii | Hussein, Maen | Lim, Farah Louise | Yang, Cheng-Ta | ... | Johnson, Melissa
Lung Cancer, volume 186 (2023).
10.1016/j.lungcan.2023.107422
Cited by (1) | Cite | Source
146 HLA-B44 motif neoepitope is associated with an anti-tumor immune microenvironment and predicts response to immune checkpoint blockade in non-small cell lung cancer (conference)
Li, Rui | Fares, Charlene | Zhang, Tianhao | Grogan, Tristan | Velez, Maria | Ayzenberg, Gregory | Radwan, Yazeed | Lind-lebuffe, Jackson | Brodrick, Paige | Elashoff, David | ... | Garon, Edward
SITC 38th Annual Meeting (SITC 2023) Abstracts (2023)
10.1136/jitc-2023-SITC2023.0146
Cite | Source
P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON (journal article)
Cho, B.C. | Diaz Perez, I. | Lowery, C. | Szadkowski, L. | Peters, S. | Garon, E.B. | Mok, T. | Johnson, M.L.
Journal of Thoracic Oncology, volume 18, issue 11, pages S318-S319 (2023).
10.1016/j.jtho.2023.09.551
Cite | Source
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 (journal article)
Shimizu, Toshio | Sands, Jacob | Yoh, Kiyotaka | Spira, Alexander | Garon, Edward B. | Kitazono, Satoru | Johnson, Melissa L. | Meric-Bernstam, Funda | Tolcher, Anthony W. | Yamamoto, Noboru | ... | Heist, Rebecca S.
Journal of Clinical Oncology, volume 41, issue 29, pages 4678-4687 (2023).
10.1200/JCO.23.00059
Cited by (29) | Cite | Source
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review (journal article)
Garon, Edward B. | Visseren-Grul, Carla | Rizzo, Maria Teresa | Puri, Tarun | Chenji, Suresh | Reck, Martin
Frontiers in Oncology, volume 13 (2023).
10.3389/fonc.2023.1247879
Cited by (5) | Cite | Source
Consent document translation expense hinders inclusive clinical trial enrolment (journal article)
Velez, Maria A. | Glenn, Beth A. | Garcia-Jimenez, Maria | Cummings, Amy L. | Lisberg, Aaron | Nañez, Andrea | Radwan, Yazeed | Lind-Lebuffe, Jackson P. | Brodrick, Paige M. | Li, Debory Y. | ... | Garon, Edward B.
Nature, volume 620, issue 7975, pages 855-862 (2023).
10.1038/s41586-023-06382-0
Cited by (5) | Cite | Source
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results (journal article)
Garon, E.B. | Reck, M. | Nishio, K. | Heymach, J.V. | Nishio, M. | Novello, S. | Paz-Ares, L. | Popat, S. | Aix, S. Ponce | Graham, H. | ... | Nakagawa, K.
ESMO Open, volume 8, issue 4, pages 101580- (2023).
10.1016/j.esmoop.2023.101580
Cited by (3) | Cite | Source
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial (journal article)
Garon, Edward B. | Spira, Alexander I. | Goldberg, Sarah B. | Chaft, Jamie E. | Papadimitrakopoulou, Vassiliki | Cascone, Tina | Antonia, Scott J. | Brahmer, Julie R. | Camidge, D. Ross | Powderly, John D. | ... | Awad, Mark M.
Journal of Thoracic Oncology, volume 18, issue 8, pages 1094-1102 (2023).
10.1016/j.jtho.2023.04.020
Cited by (1) | Cite | Source
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome (journal article)
Nishio, Makoto | Paz-Ares, Luis | Reck, Martin | Nakagawa, Kazuhiko | Garon, Edward B. | Popat, Sanjay | Ceccarelli, Matteo | Graham, Hillary T. | Visseren-Grul, Carla | Novello, Silvia
Clinical Lung Cancer, volume 24, issue 5, pages 415-428 (2023).
10.1016/j.cllc.2023.02.010
Cited by (8) | Cite | Source
UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer. (journal article)
Goldman, Jonathan W. | Cummings, Amy Lauren | Arzoo, Karo K. | Hu, Eddie Hong-Lung | Garon, Edward B. | Kirimis, Evangelia K. | Olevsky, Olga | DiCarlo, Brian Anthony | Davidson, Sheldon J. | Kaul, Anita | ... | Slamon, Dennis J.
Journal of Clinical Oncology, volume 41, issue 16_suppl, pages e21165-e21165 (2023).
10.1200/JCO.2023.41.16_suppl.e21165
Cite | Source
Translated consent documents (CDs) and use in non-industry sponsored studies (NISS). (journal article)
Velez, Maria A | Glenn, Beth A | Garcia-Jimenez, Maria De Lourdes | Cummings, Amy Lauren | Lisberg, Aaron Elliott | Nañez, Andrea | Radwan, Yazeed | Lind-Lebuffe, Jackson P | Brodrick, Paige M | Gower, Arjan | ... | Garon, Edward B.
Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 6553-6553 (2023).
10.1200/JCO.2023.41.16_suppl.6553
Cite | Source